Portret kobiety z zaczerwienioną skórą twarzy

Ivermectin for Rosacea — How Does It Compare to Azelaic Acid?

Rosacea is a completely different disease from common acne, despite the confusingly similar name — and it needs different treatment. Ivermectin 1% cream is one of the newer treatment options, tested in two 40-week extension trials against azelaic acid 15%. We explain exactly what these trials showed, what they didn't show, and why this is primarily long-term safety data rather than a classic head-to-head efficacy contest.

AKdr Anna KowalczykAugust 27, 202611 min read

Table of contents

TL;DR — key takeaways

→Rosacea is not just "acne that won't go away"
→Where the idea of ivermectin for rosacea came from
→What the trial comparing ivermectin with azelaic acid showed
→What this means for treatment choice in practice
→The myth that delays proper treatment
→Before you reach for any product
→Limitations of this data
→Our editorial recommendation

Rosacea is not just "acne that won't go away"

The name is misleading, and that's the main source of confusion: rosacea is not a variant or prolonged form of common acne, but a separate, chronic inflammatory skin disease of the face. It primarily involves blood vessels and the skin's innate immune mechanisms, not sebaceous glands clogged by excess sebum and dead skin cells, as in classic teenage acne. In practice, this means that treatments effective for common acne — strong exfoliating agents, some oral antibiotics used differently than in rosacea, aggressive peels — can be ineffective in rosacea, and sometimes even worsen symptoms.

The clinical picture is also different. Rosacea typically affects the central part of the face — cheeks, nose, forehead, chin — and causes persistent redness, visible dilated blood vessels (telangiectasia), and in the papulopustular form, also red papules and pustules resembling acne, but without the typical comedones. In some patients, tissue overgrowth develops, mainly around the nose (rhinophyma), and the disease can also be associated with eye irritation (ocular rosacea). This article focuses on the papulopustular form, since that's exactly what the trial discussed below evaluated for ivermectin.

Where the idea of ivermectin for rosacea came from

Ivermectin is known primarily as an antiparasitic drug, used for decades to treat scabies and certain parasitic infestations, among other things. Its presence in rosacea dermatology stems from a hypothesis studied for years: some rosacea patients have elevated numbers of Demodex folliculorum mites, tiny parasites that naturally live in the hair follicles of facial skin, which in excess may worsen local inflammation. Ivermectin has both antiparasitic activity against Demodex and a direct anti-inflammatory effect independent of the mites themselves.

This is still a studied hypothesis, not an established fact

The link between Demodex mite counts and rosacea severity is the subject of active research, not a fully confirmed causal mechanism. Ivermectin may work both by reducing Demodex and through independent anti-inflammatory action — the clinical trial discussed in this article evaluated the end result (safety and skin condition), not which of these mechanisms is responsible for it.

Ivermectin 1% cream received approval for treating inflammatory lesions of papulopustular rosacea after two earlier phase III trials showed its superiority over placebo (vehicle without active substance) in reducing skin lesions and overall clinical assessment. It was the participants of those two phase III trials who were later invited to a longer follow-up, described in the next section of this article.

What the trial comparing ivermectin with azelaic acid showed

Azelaic acid at a 15% concentration is one of the established, long-used topical therapies for papulopustular rosacea, with a well-documented safety profile. A natural clinical question, then, was how the newer ivermectin cream compares to it over longer, multi-month use — not just versus placebo.

Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials

Moderate evidence

Stein Gold L, Kircik L, Fowler J, Jackson JM, Tan J, Draelos Z et al. (Ivermectin Phase 3 Study Group) · Journal of Drugs in Dermatology · 2014

Two 40-week extension trials, continuing earlier phase III trials of ivermectin 1% cream in papulopustular rosacea. Participants originally treated with ivermectin 1% continued that therapy, while participants originally receiving placebo (vehicle) were switched to azelaic acid 15% gel — total treatment time reached up to 52 weeks. Ivermectin 1% cream proved safe throughout the follow-up period, with a lower rate of treatment-related adverse events compared to the azelaic acid group. No participant in the ivermectin group discontinued the study due to a treatment-related adverse event. Ivermectin's efficacy was maintained during the extended follow-up — the proportion of patients with an IGA (Investigator Global Assessment) rating of "clear" or "almost clear" skin was higher at the end of the study than at the start. The publication does not report the exact group sizes or percentage values or p-values for the adverse event comparison — the abstract is limited to descriptive conclusions.

View study

This is a safety study, not a classic efficacy showdown

Moderate evidence

It's worth being precise about what this research project actually evaluated. It was a long-term safety and tolerability project (safety extension study), not a randomized head-to-head trial in which both groups were randomly assigned to ivermectin or azelaic acid from the start. In practice: the ivermectin group consisted of people continuing a therapy they had already tolerated well, while the azelaic acid group consisted of people who had received placebo in the original trial and only switched to active treatment in the extension phase. This setup naturally favors a better safety profile in the group continuing an already-known therapy and makes it harder to cleanly interpret the difference in adverse events between the two substances.

What this means for treatment choice in practice

The trial result — fewer treatment-related adverse events with ivermectin than with azelaic acid under long-term use conditions — is valuable information, but it shouldn't be read as proof that ivermectin is generally "better" than azelaic acid. The two substances have different tolerability profiles: azelaic acid is more often associated with local burning, itching, or skin irritation, especially early in therapy, while ivermectin showed generally good skin tolerability in registration trials. Which option works better for a specific person also depends on the severity of lesions, skin sensitivity, and prior experience with other topical therapies.

Ivermectin 1% is today one of several recognized first-line options for topical treatment of papulopustular rosacea, alongside azelaic acid and metronidazole — the choice between them is a decision for a dermatologist, individually tailored, not a matter of one universally "best" substance confirmed by a single trial.

The myth that delays proper treatment

Myth

Since it's called "rosacea," the same cosmetics and anti-acne treatments used for ordinary acne should work — you just need to wait longer for results.

Fact

Rosacea and common acne have different underlying disease mechanisms and different first-line treatments. Popular anti-acne products based on strong exfoliating acids or high concentrations of benzoyl peroxide, helpful in common acne, often irritate the already sensitive, reactive skin in rosacea and worsen redness instead of easing it. Correctly distinguishing between these two diseases is a prerequisite for choosing effective treatment.

An added diagnostic difficulty: rosacea is often confused not only with common acne, but also with seborrheic dermatitis, contact dermatitis, lupus erythematosus, or simple sunburn-related redness — some of these conditions require completely different management. Diagnosing it yourself "by eye" and reaching for a random pharmacy cream without consultation carries a real risk of worsening the skin condition or wasting time treating the wrong cause.

Before you reach for any product

Practical steps if you suspect rosacea

Consult a dermatologist to confirm the diagnosis — rosacea is often confused with several other skin conditions requiring different treatment
Don't reach for strong anti-acne products (high-concentration acids, benzoyl peroxide) on your own without consultation — they may worsen redness
Observe and note factors that worsen symptoms (alcohol, spicy foods, hot beverages, stress, UV radiation, high temperature) — this is common and helpful information for your doctor
Use daily sun protection (SPF cream) year-round — UV radiation is one of the more common rosacea-aggravating factors
Choose gentle, hypoallergenic products for daily skincare, avoiding products with alcohol, menthol, or strong fragrances
If your doctor prescribes ivermectin or azelaic acid cream, give the therapy enough time — effects in rosacea usually appear gradually, over several weeks to a few months

Limitations of this data

What this trial doesn't prove

The publication described in this article has several notable limitations worth remembering. First, the available abstract doesn't report the exact number of participants in each group, nor specific percentage values, confidence intervals, or statistical significance levels for the adverse event comparison — the conclusions in the abstract are descriptive, not fully quantitative. Second, as described above, this was not a classic randomized head-to-head comparison of two therapies from the same starting point, which limits the ability to definitively state that ivermectin is "safer" than azelaic acid in a strict, controlled sense. Third, the trial was investigator-blinded (blinding on the evaluating physician's side), not full double-blinding of both parties. Finally, the results apply to a specific form of the disease — papulopustular rosacea — and shouldn't be automatically extended to other forms of rosacea, such as the vascular-erythematous or ocular form.

Question	Short answer
Is rosacea the same as common acne?	No — it's a separate inflammatory disease of the facial blood vessels and skin, requiring different treatment
What did the 2014 trial show?	Ivermectin 1% cream had fewer treatment-related adverse events than azelaic acid 15% over up to 52 weeks of follow-up
Was this a full efficacy showdown between the two substances?	Not exactly — it's mainly long-term safety data from a trial with a non-randomized group setup relative to each other
Is ivermectin generally better than azelaic acid?	There's no clear evidence for that — both are recognized first-line options with different tolerability profiles
Can rosacea be self-diagnosed?	It's not recommended — symptoms are easily confused with other skin conditions, including common acne

Ivermectin vs azelaic acid for rosacea — at a glance

Our editorial recommendation

Ivermectin 1% cream has solid grounds as a treatment option for papulopustular rosacea, confirmed both by phase III trials against placebo and by longer-term safety follow-up against azelaic acid. However, this is not proof of clear superiority over other recognized therapies — it's rather confirmation that ivermectin is a safe, well-tolerated option worth considering alongside azelaic acid and metronidazole, with the final decision belonging to the treating dermatologist.

The most important step in rosacea isn't chemical, it's diagnostic: before anyone chooses between ivermectin and azelaic acid, it's worth being sure this is actually rosacea and not another, similar-looking skin condition.

dr Anna Kowalczyk, VitMode editorial team

Frequently asked questions

Rosacea is a chronic inflammatory disease primarily affecting the blood vessels and innate immunity of the central facial skin, presenting as persistent redness, visible blood vessels, and in some forms, papules and pustules. Common acne, by contrast, results mainly from sebum overproduction, clogged hair follicles, and bacterial proliferation, more often affects younger people, and produces typical comedones. These are two different diseases with different treatments, despite the similar-sounding name.

The trial discussed (Stein Gold et al., 2014) was not a classic, randomized efficacy comparison of both substances from the same starting point — it mainly evaluated long-term safety in a setup where the ivermectin group continued a previously tolerated therapy, while the azelaic acid group was only beginning active treatment after prior placebo. Ivermectin had fewer treatment-related adverse events, but that's not equivalent to proven superior clinical efficacy over azelaic acid.

Some rosacea patients have elevated numbers of Demodex folliculorum mites, which is a studied hypothesis explaining part of the disease mechanism — not a fully confirmed causal fact. Ivermectin acts both as an antiparasitic against Demodex and directly as an anti-inflammatory, so its clinical efficacy doesn't necessarily mean that mite reduction is what's responsible for skin improvement.

In clinical trials, effects were assessed after several weeks to a few months of use, and in the extension trial discussed here, improvement was observed over a total treatment period of up to 40-52 weeks. Rosacea is a chronic disease, so effects appear gradually, and therapy is often continued long-term under a dermatologist's supervision, rather than used briefly like for a single breakout.

Rosacea is a chronic, relapsing disease — available topical therapies, including ivermectin and azelaic acid, control symptoms and reduce inflammatory lesions, but don't constitute a one-time, permanent cure. Many patients require long-term, sometimes seasonally adjusted management, including avoiding known aggravating factors.

Azelaic acid 15% is an established, long-used topical therapy for rosacea with a generally good safety profile. In the trial discussed, the azelaic acid group had more treatment-related adverse events than the group continuing ivermectin, but this difference may partly reflect the trial's setup rather than the substance alone — azelaic acid remains a recognized, safe first-line option.

This isn't recommended without prior dermatological consultation. Facial redness can have many causes besides rosacea, and using the wrong product without a confirmed diagnosis may not only fail to help, but also delay proper treatment or irritate the skin. A dermatologist will confirm the diagnosis and select therapy appropriate to the form and severity of the condition.

Sources

Stein Gold et al. 2014 — Journal of Drugs in Dermatology

dr Anna Kowalczyk

PhD in Molecular Biology (University of Warsaw), 8 years researching cellular aging

Anna oversees the editorial process and scientific review of every publication in the knowledge base. She previously researched autophagy and mitochondrial biology.

Mężczyzna w szlafroku myjący twarz przy umywalce

TRT and Acne — Why Can Testosterone Cause Skin Problems?

Acne is the most common skin side effect of testosterone therapy — yet patients are rarely told exactly why it happens or what to actually do about it. We break down the sebaceous-gland mechanism step by step and lay out the full treatment ladder, from skincare to a dermatologist.

13 min

August 15, 2026

Uśmiechnięta kobieta trzymająca produkt do pielęgnacji skóry z trądzikiem

Benzoyl Peroxide Plus Clindamycin vs Azelaic Acid — What a Head-to-Head Trial Shows in Acne Vulgaris

Acne vulgaris is one of the most common skin conditions, and pharmacy shelves offer several proven topical treatments competing for attention. Azelaic acid is often marketed as a gentler, "natural" alternative, while benzoyl peroxide combined with clindamycin is positioned as a proven, stronger classic. One of the few direct head-to-head trials, published in the Journal of the European Academy of Dermatology and Venereology, pitted both regimens against each other in more than 200 patients with mild-to-moderate acne — and the result is not as clear-cut as the "gentler option" marketing narrative would suggest.

11 min

August 27, 2026

Elegancka kompozycja z pojemnikiem kolagenu w proszku obok zielonych liści i białych kwiatów

Which Collagen Should You Choose? Type I, II and III — What the Research Actually Says

Collagen is one of the most commonly bought supplements in Poland, yet few people know that 'collagen' isn't a single substance — it's a family of proteins with different uses. We explain the difference and help you pick the right type.

10 min

August 18, 2026

Kobieta w szlafroku aplikująca krem do twarzy

Collagen and Skin Health: What Do Two Meta-Analyses Show?

Collagen powder or capsules are one of the fastest-growing segments of the beauty supplement market — and, rare for this category, one of the few where the popular promise ("firmer, better-hydrated skin") has earned solid confirmation in two independent, well-designed meta-analyses. This is a rare situation in supplement science, worth a closer look precisely because the evidence here is unusually consistent.